| PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients HR Kim, SJ Ha, MH Hong, SJ Heo, YW Koh, EC Choi, EK Kim, KH Pyo, ... Scientific reports 6 (1), 36956, 2016 | 246 | 2016 |
| Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer CG Kim, KH Kim, KH Pyo, CF Xin, MH Hong, BC Ahn, Y Kim, SJ Choi, ... Annals of Oncology 30 (7), 1104-1113, 2019 | 208 | 2019 |
| Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC J Yun, SH Lee, SY Kim, SY Jeong, JH Kim, KH Pyo, CW Park, SG Heo, ... Cancer Discovery 10 (8), 1194-1209, 2020 | 148* | 2020 |
| Immunotherapy for non-small cell lung cancer: current landscape and future perspectives SM Lim, MH Hong, HR Kim Immune Network 20 (1), 2020 | 99 | 2020 |
| Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open … MJ Ahn, JY Han, KH Lee, SW Kim, DW Kim, YG Lee, EK Cho, JH Kim, ... The Lancet Oncology 20 (12), 1681-1690, 2019 | 99 | 2019 |
| Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea MH Hong, HS Kim, C Kim, JR Ahn, HJ Chon, SJ Shin, JB Ahn, HC Chung, ... Cancer research and treatment: official journal of Korean Cancer Association …, 2009 | 83 | 2009 |
| Impact of treatment-related lymphopenia on immunotherapy for advanced non-small cell lung cancer Y Cho, S Park, HK Byun, CG Lee, J Cho, MH Hong, HR Kim, BC Cho, ... International Journal of Radiation Oncology* Biology* Physics 105 (5), 1065-1073, 2019 | 81 | 2019 |
| Characteristics and outcome of ROS1-positive non–small cell lung cancer patients in routine clinical practice S Park, BC Ahn, SW Lim, JM Sun, HR Kim, MH Hong, SH Lee, JS Ahn, ... Journal of Thoracic Oncology 13 (9), 1373-1382, 2018 | 77 | 2018 |
| Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer JW Cho, MH Hong, SJ Ha, YJ Kim, BC Cho, I Lee, HR Kim Experimental & Molecular Medicine 52 (9), 1550-1563, 2020 | 71 | 2020 |
| YH25448, an irreversible EGFR-TKI with potent intracranial activity in EGFR mutant non–small cell lung cancer J Yun, MH Hong, SY Kim, CW Park, S Kim, MR Yun, HN Kang, KH Pyo, ... Clinical Cancer Research 25 (8), 2575-2587, 2019 | 69 | 2019 |
| Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice BC Ahn, KH Pyo, CF Xin, D Jung, HS Shim, CY Lee, SY Park, HI Yoon, ... Journal of cancer research and clinical oncology 145, 1613-1623, 2019 | 67 | 2019 |
| Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles HS Kim, MH Hong, K Kim, SJ Shin, JB Ahn, HC Jeung, HC Chung, Y Koh, ... Oncology 80 (5-6), 395-405, 2011 | 63 | 2011 |
| Clinical value of ezrin expression in primary osteosarcoma C Kim, E Shin, S Hong, HJ Chon, HR Kim, JR Ahn, MH Hong, WI Yang, ... Cancer research and treatment: official journal of Korean Cancer Association …, 2009 | 61 | 2009 |
| Repotrectinib exhibits potent antitumor activity in treatment-naïve and solvent-front–mutant ROS1-rearranged non–small cell lung cancer MR Yun, DH Kim, SY Kim, HS Joo, YW Lee, HM Choi, CW Park, SG Heo, ... Clinical Cancer Research 26 (13), 3287-3295, 2020 | 54 | 2020 |
| Blocking TIM-3 in treatment-refractory advanced solid tumors: a phase Ia/b study of LY3321367 with or without an anti-PD-L1 antibody JJ Harding, V Moreno, YJ Bang, MH Hong, A Patnaik, J Trigo, ... Clinical Cancer Research 27 (8), 2168-2178, 2021 | 51 | 2021 |
| Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma HR Kim, HN Kang, HS Shim, EY Kim, J Kim, DJ Kim, JG Lee, CY Lee, ... Annals of Oncology 28 (6), 1250-1259, 2017 | 48 | 2017 |
| Docetaxel versus paclitaxel combined with 5-FU and leucovorin in advanced gastric cancer: combined analysis of two phase II trials HJ Chon, SY Rha, CK Im, C Kim, MH Hong, HR Kim, JR An, SH Noh, ... Cancer Research and Treatment: Official Journal of Korean Cancer Association …, 2009 | 46 | 2009 |
| A phase II trial of preoperative chemoradiotherapy and pembrolizumab for locally advanced esophageal squamous cell carcinoma (ESCC). MH Hong, HR Kim, SY Park, DJ Kim, CG Lee, J Cho, JH Kim, HR Kim, ... Journal of Clinical Oncology 37 (15_suppl), 4027-4027, 2019 | 44 | 2019 |
| Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK‐rearranged lung cancer MR Yun, HM Choi, YW Lee, HS Joo, CW Park, JW Choi, DH Kim, ... EMBO molecular medicine 11 (12), e10581, 2019 | 43 | 2019 |
| Enhancer remodeling and MicroRNA alterations are associated with acquired resistance to ALK inhibitors MR Yun, SM Lim, SK Kim, HM Choi, KH Pyo, SK Kim, JM Lee, YW Lee, ... Cancer research 78 (12), 3350-3362, 2018 | 41 | 2018 |
